Novo Nordisk's (NYSE: NVO) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is indicated for type 2 diabetes, Wegovy is prescribed for weight loss in the context of obesity. But, if some new information holds true, the company could soon see its presence in both of those markets take a hit.

Here's what was just discovered and why it matters.

Continue reading

Source Fool.com